Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 5/20 | 0.31 |
| ▸ | HTR1D | P28221 | 3/20 | 0.31 |
| ▸ | HTR1B | P28222 | 3/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821273 | 0.90 | IKBKB (0.32) | PTGDR2IKBKB | |
| SCHEMBL23999784 | 0.85 | DRD2 (0.36) | CHRM3DRD2DRD1PTGDR2CHRM2 | |
| SCHEMBL25820235 | 0.81 | IKBKB (0.32) | IKBKB | |
| SCHEMBL25822499 | 0.80 | ADAM17 (0.31) | IKBKB | |
| SCHEMBL25820234 | 0.76 | HTR2A (0.34) | HTR1D | |
| SCHEMBL25831651 | 0.75 | CHRM3 (0.35) | CHRM3DRD2DRD1CHRM2CHRM1 | |
| SCHEMBL25820238 | 0.74 | NOS3 (0.42) | IKBKB | |
| SCHEMBL25846522 | 0.74 | CHRM2 (0.50) | CHRM3DRD2DRD1CHRM2CHRM1 | |
| SCHEMBL24003780 | 0.74 | DRD2 (0.36) | CHRM3DRD2DRD1CHRM2CHRM1 | |
| SCHEMBL25821294 | 0.73 | KMT2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CHRM3 2950/4885DRD2 4881/4885DRD1 4879/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CHRM3 2791/4885DRD2 4874/4885DRD1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.